KPV

KPV (10mg) — Research Peptide

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH), a 13-amino acid neuropeptide with established anti-inflammatory properties. Unlike the full α-MSH peptide, KPV does not bind melanocortin receptors with significant affinity, instead exerting its documented anti-inflammatory effects through direct intracellular mechanisms — primarily inhibition of NF-κB activation, a central pathway in inflammatory signalling.

Mechanism of Action

KPV’s primary research-characterised mechanism involves inhibition of the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signalling pathway. NF-κB is a master transcription factor driving expression of pro-inflammatory cytokines including IL-1β, IL-6, IL-8, and TNF-α. KPV penetrates epithelial cells and inhibits IκB kinase (IKK) phosphorylation, preventing IκB degradation and subsequent NF-κB nuclear translocation.

Research by Dalmasso et al. (2008) demonstrated KPV’s ability to reduce inflammatory cytokine expression in intestinal epithelial cells, with effects comparable to the parent α-MSH molecule despite KPV’s lack of melanocortin receptor affinity. This suggests a receptor-independent intracellular mechanism distinct from typical neuropeptide signalling.

Research Applications

• Intestinal inflammation models (IBD, colitis)
• Skin inflammatory biology research
• NF-κB pathway investigation
• Nanoparticle drug delivery research (oral and topical KPV delivery studies)
• Wound healing and barrier function research

Product Specifications

• Peptide: KPV (Lys-Pro-Val)
• Dose: 10mg per vial
• Format: Lyophilised powder, bulk box of 10 vials
• Purity: ≥98% Janoshik HPLC verified
• Storage: -20°C. 24-month stability.

For laboratory research use only. Not for human therapeutic use.